Posted by Michael Wonder on 23 Sep 2023
argenx announces Vyvgart (efgartigimod alfa) authorised for sale by Health Canada for generalised myasthenia gravis
21 September 2023 - Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of Vyvgart treated patients were responders on the MG-ADL scale compared to 30% of placebo patients after one treatment cycle.
Argenx today announced that Health Canada has issued a Notice of Compliance authorizing Vyvgart (efgartigimod alfa) for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
